vs
BXP, Inc.（BXP）与百利高（PRGO）财务数据对比。点击上方公司名可切换其他公司
百利高的季度营收约是BXP, Inc.的1.3倍（$1.1B vs $872.1M），BXP, Inc.净利率更高（15.3% vs -127.8%，领先143.1%），BXP, Inc.同比增速更快（0.8% vs -2.5%），过去两年BXP, Inc.的营收复合增速更高（1.3% vs 1.3%）
BXP是美国头部商业地产投资信托企业，核心业务为持有、运营及开发A级高端写字楼资产，项目覆盖纽约、波士顿、旧金山等美国核心都市圈，服务企业、科技、专业服务等领域的多元租户。
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
BXP vs PRGO — 直观对比
营收规模更大
PRGO
是对方的1.3倍
$872.1M
营收增速更快
BXP
高出3.3%
-2.5%
净利率更高
BXP
高出143.1%
-127.8%
两年增速更快
BXP
近两年复合增速
1.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $872.1M | $1.1B |
| 净利润 | $133.0M | $-1.4B |
| 毛利率 | — | 32.6% |
| 营业利润率 | — | -116.0% |
| 净利率 | 15.3% | -127.8% |
| 营收同比 | 0.8% | -2.5% |
| 净利润同比 | 53.0% | -3093.9% |
| 每股收益（稀释后） | $1.69 | $-10.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BXPPRGO
| Q1 26 | $872.1M | — | ||
| Q4 25 | $877.1M | $1.1B | ||
| Q3 25 | $871.5M | $1.0B | ||
| Q2 25 | $868.5M | $1.1B | ||
| Q1 25 | $865.2M | $1.0B | ||
| Q4 24 | $858.6M | $1.1B | ||
| Q3 24 | $859.2M | $1.1B | ||
| Q2 24 | $850.5M | $1.1B |
净利润BXPPRGO
| Q1 26 | $133.0M | — | ||
| Q4 25 | $248.4M | $-1.4B | ||
| Q3 25 | $-121.7M | $7.5M | ||
| Q2 25 | $89.0M | $-8.4M | ||
| Q1 25 | $61.2M | $-6.4M | ||
| Q4 24 | $-228.9M | $-44.4M | ||
| Q3 24 | $83.6M | $-21.0M | ||
| Q2 24 | $79.6M | $-108.4M |
毛利率BXPPRGO
| Q1 26 | — | — | ||
| Q4 25 | 58.8% | 32.6% | ||
| Q3 25 | 59.3% | 36.1% | ||
| Q2 25 | 59.2% | 34.4% | ||
| Q1 25 | 59.2% | 37.6% | ||
| Q4 24 | 59.7% | 33.9% | ||
| Q3 24 | 59.5% | 37.2% | ||
| Q2 24 | 59.8% | 37.0% |
营业利润率BXPPRGO
| Q1 26 | — | — | ||
| Q4 25 | — | -116.0% | ||
| Q3 25 | — | 7.0% | ||
| Q2 25 | — | 4.3% | ||
| Q1 25 | — | 4.5% | ||
| Q4 24 | — | 10.0% | ||
| Q3 24 | — | 7.4% | ||
| Q2 24 | — | -2.5% |
净利率BXPPRGO
| Q1 26 | 15.3% | — | ||
| Q4 25 | 28.3% | -127.8% | ||
| Q3 25 | -14.0% | 0.7% | ||
| Q2 25 | 10.2% | -0.8% | ||
| Q1 25 | 7.1% | -0.6% | ||
| Q4 24 | -26.7% | -3.9% | ||
| Q3 24 | 9.7% | -1.9% | ||
| Q2 24 | 9.4% | -10.2% |
每股收益（稀释后）BXPPRGO
| Q1 26 | $1.69 | — | ||
| Q4 25 | $1.56 | $-10.23 | ||
| Q3 25 | $-0.77 | $0.05 | ||
| Q2 25 | $0.56 | $-0.06 | ||
| Q1 25 | $0.39 | $-0.05 | ||
| Q4 24 | $-1.46 | $-0.32 | ||
| Q3 24 | $0.53 | $-0.15 | ||
| Q2 24 | $0.51 | $-0.79 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $512.8M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $7.7B | $2.9B |
| 总资产 | $25.1B | $8.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BXPPRGO
| Q1 26 | $512.8M | — | ||
| Q4 25 | $1.5B | — | ||
| Q3 25 | $861.1M | $432.1M | ||
| Q2 25 | $447.0M | $454.2M | ||
| Q1 25 | $398.1M | $409.9M | ||
| Q4 24 | $1.3B | $558.8M | ||
| Q3 24 | $1.4B | $1.5B | ||
| Q2 24 | $685.4M | $542.8M |
股东权益BXPPRGO
| Q1 26 | $7.7B | — | ||
| Q4 25 | $5.1B | $2.9B | ||
| Q3 25 | $5.0B | $4.4B | ||
| Q2 25 | $5.3B | $4.5B | ||
| Q1 25 | $5.3B | $4.4B | ||
| Q4 24 | $5.4B | $4.3B | ||
| Q3 24 | $5.8B | $4.6B | ||
| Q2 24 | $5.8B | $4.5B |
总资产BXPPRGO
| Q1 26 | $25.1B | — | ||
| Q4 25 | $26.2B | $8.5B | ||
| Q3 25 | $26.0B | $10.1B | ||
| Q2 25 | $25.6B | $10.1B | ||
| Q1 25 | $25.4B | $9.8B | ||
| Q4 24 | $26.1B | $9.6B | ||
| Q3 24 | $26.4B | $11.2B | ||
| Q2 24 | $25.5B | $10.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $175.4M |
| 自由现金流经营现金流 - 资本支出 | — | $148.6M |
| 自由现金流率自由现金流/营收 | — | 13.4% |
| 资本支出强度资本支出/营收 | 1.5% | 2.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $145.1M |
8季度趋势，按日历期对齐
经营现金流BXPPRGO
| Q1 26 | — | — | ||
| Q4 25 | $407.8M | $175.4M | ||
| Q3 25 | $274.2M | $51.7M | ||
| Q2 25 | $353.1M | $75.9M | ||
| Q1 25 | $210.0M | $-64.5M | ||
| Q4 24 | $383.7M | $312.6M | ||
| Q3 24 | $286.1M | $42.2M | ||
| Q2 24 | $367.1M | $9.5M |
自由现金流BXPPRGO
| Q1 26 | — | — | ||
| Q4 25 | $362.7M | $148.6M | ||
| Q3 25 | $231.6M | $29.8M | ||
| Q2 25 | $281.5M | $56.7M | ||
| Q1 25 | $152.6M | $-90.0M | ||
| Q4 24 | $312.5M | $274.9M | ||
| Q3 24 | $234.5M | $15.1M | ||
| Q2 24 | $332.4M | $-18.9M |
自由现金流率BXPPRGO
| Q1 26 | — | — | ||
| Q4 25 | 41.4% | 13.4% | ||
| Q3 25 | 26.6% | 2.9% | ||
| Q2 25 | 32.4% | 5.4% | ||
| Q1 25 | 17.6% | -8.6% | ||
| Q4 24 | 36.4% | 24.2% | ||
| Q3 24 | 27.3% | 1.4% | ||
| Q2 24 | 39.1% | -1.8% |
资本支出强度BXPPRGO
| Q1 26 | 1.5% | — | ||
| Q4 25 | 5.1% | 2.4% | ||
| Q3 25 | 4.9% | 2.1% | ||
| Q2 25 | 8.2% | 1.8% | ||
| Q1 25 | 6.6% | 2.4% | ||
| Q4 24 | 8.3% | 3.3% | ||
| Q3 24 | 6.0% | 2.5% | ||
| Q2 24 | 4.1% | 2.7% |
现金转化率BXPPRGO
| Q1 26 | — | — | ||
| Q4 25 | 1.64× | — | ||
| Q3 25 | — | 6.89× | ||
| Q2 25 | 3.97× | — | ||
| Q1 25 | 3.43× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.42× | — | ||
| Q2 24 | 4.61× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BXP
| Lease | $818.2M | 94% |
| Parking and other | $30.8M | 4% |
| Development and management services | $9.2M | 1% |
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
